In December 2017, NICE published a technology appraisal (TA494) on the combination product Mysimba containing naltrexone-bupropion and its use as an adjunct in helping manage overweight and obesity. NICE did not recommend naltrexone-bupropion for NHS use despite the product having a marketing authorisation for managing overweight and obesity in adults alongside a reduced-calorie diet and increased physical activity.

However, patients who had been started on naltrexone-bupropion before TA494 was published should be able to continue being treated with it being funded by the NHS, until they and their NHS clinicians consider it appropriate to stop, said NICE.